CEA is Primarily a Marker for Colorectal Cancer
CEA (carcinoembryonic antigen) is primarily a tumor marker for colorectal cancer, used for staging, postoperative surveillance, and monitoring treatment response—not for screening or diagnosis. 1
Primary Clinical Applications in Colorectal Cancer
Based on ASCO guidelines, CEA serves four distinct roles in colorectal cancer management 1:
1. Preoperative Staging
- CEA may be ordered before surgery to assist in staging and surgical planning
- Elevated preoperative CEA (≥5 mg/mL) correlates with poorer prognosis
- Provides baseline for postoperative surveillance utility
- Also indicated before resection of liver metastases, where it predicts prognosis 1
2. Postoperative Surveillance
Measure CEA every 3 months for at least 3 years after diagnosis in stage II or III disease, but only if the patient is a surgical or systemic therapy candidate. 1
- An elevated CEA (confirmed by retesting) warrants further metastatic workup
- Wait until chemotherapy completion before initiating surveillance, as chemotherapy can falsely elevate CEA 1
- The rationale: early detection of recurrence allows intervention when systemic therapy can improve survival 1
3. Monitoring Metastatic Disease
CEA is the marker of choice for monitoring metastatic colorectal cancer during systemic therapy. 1
- Measure at treatment start and every 1-3 months during active treatment
- Persistently rising values suggest progressive disease even without radiographic confirmation
- Critical caveat: Spurious early rises can occur in the first 4-6 weeks of new therapy, especially with oxaliplatin—interpret cautiously 1
4. What CEA Should NOT Be Used For
- Not for screening: Sensitivity is too low despite high specificity 1
- Not for diagnosis: Cannot independently establish cancer diagnosis 2
- Not for determining adjuvant therapy: Insufficient data to guide treatment decisions based on CEA alone 1
- Not as sole justification for systemic therapy: Elevated CEA alone doesn't warrant treatment without confirmatory imaging 1
Beyond Colorectal Cancer
While CEA is most established for colorectal cancer, it can be elevated in other conditions 3:
Other Malignancies with CEA Elevation:
- Medullary thyroid cancer (MTC): CEA is produced by neoplastic C cells alongside calcitonin; >50% of MTC patients have elevated CEA, and it correlates with aggressive disease 4, 5
- Pancreatic cancer: One of only two localized tumors (with colorectal) that produces CEA elevation above benign disease levels 6
- Lung cancer: Elevated CEA correlates with metastatic disease burden and multiple metastases 7
- Other cancers: breast, gastric, ovarian, but marked elevation typically indicates distant metastasis 6
Non-Malignant Causes:
CEA can be elevated in benign conditions including gastritis, peptic ulcer disease, diverticulitis, liver disease, COPD, diabetes, and any acute/chronic inflammatory state 1. Healthy individuals >65 years also have higher baseline CEA levels 3.
Key Clinical Pitfalls
- False elevations during chemotherapy: Wait 4-6 weeks after starting new therapy before interpreting rising CEA as progression 1
- Benign causes: Always consider non-malignant etiologies, particularly inflammatory and liver conditions 1
- Laboratory variability: CEA levels may differ between laboratories—use consistent testing sites 1
- Age-related elevation: Elderly patients naturally have higher baseline CEA 3
- When GI workup is negative: Consider medullary thyroid cancer, especially if CEA is markedly elevated (check serum calcitonin) 4
Practical Algorithm
For an elevated CEA:
- If known colorectal cancer: Use per surveillance/monitoring guidelines above
- If no known cancer: